.Attributes Medication, Released online: 13 September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized phase 3b/4 DESTINY-Breast12 research, trastuzumab deruxtecan (T-DXd) procedure of people with HER2+ sophisticated bosom cancer as well as energetic or even stable human brain metastases presented steady intracranial task and systemic effectiveness of T-DXd.